{"entity":{"id":"cornerstone-pharmaceuticals","kind":"company","name":"Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)","aka":["Rafael Pharmaceuticals"],"tldr":"The company behind devimistat, a drug against cancer cell metabolism that failed its phase 3 trials in pancreatic cancer and leukaemia.","summary":"Rafael Pharmaceuticals, majority owned by Rafael Holdings, developed devimistat (CPI-613) for pancreatic cancer and acute myeloid leukaemia. After both phase 3 trials missed their endpoints in 2021 and 2022 the company was renamed Cornerstone Pharmaceuticals and refocused its pipeline.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.cornerstonepharma.com"}],"tags":[],"related":[],"cancers":["pancreatic","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["devimistat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cranbury, New Jersey, United States","country":"US","companyType":"biotech","website":"https://www.cornerstonepharma.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/cornerstone-pharmaceuticals/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"devimistat","kind":"drug","name":"Devimistat","route":"/drugs/devimistat/"}]}}